Olmecar-Plus
Generic Name
Olmesartan Medoxomil + Hydrochlorothiazide (20 mg + 12.5 mg) Tablet
Manufacturer
Renata Limited
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmecar plus 20 mg tablet | ৳ 10.00 | ৳ 100.00 |
Description
Overview of the medicine
Olmecar-Plus 20 mg Tablet is a combination medicine containing Olmesartan Medoxomil (an Angiotensin II Receptor Blocker) and Hydrochlorothiazide (a thiazide diuretic). It is primarily used to treat essential hypertension in adults when monotherapy is not sufficient. This combination helps to lower blood pressure by relaxing blood vessels and increasing the excretion of salt and water.
Uses & Indications
Dosage
Adults
Usually one Olmecar-Plus 20 mg tablet once daily. The dose can be increased after 2-4 weeks if blood pressure is not adequately controlled. Maximum dose is one Olmecar-Plus 40 mg tablet once daily.
Elderly
No specific dose adjustment is usually necessary for elderly patients with normal renal function. Initiate with the lowest effective dose.
Renal_impairment
Not recommended for patients with severe renal impairment (creatinine clearance <30 mL/min). For moderate impairment (creatinine clearance 30-60 mL/min), caution is advised, and monitoring of renal function and electrolytes is recommended.
How to Take
Take the tablet orally once daily with or without food. It should be swallowed whole with water.
Mechanism of Action
Olmesartan Medoxomil selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, preventing vasoconstriction and aldosterone secretion, thus lowering blood pressure. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubules, increasing the excretion of sodium, chloride, and water, leading to reduced plasma volume and a decrease in blood pressure.
Pharmacokinetics
Onset
Within 1 week, maximal effect usually within 2-4 weeks.
Excretion
Olmesartan: Approximately 35-50% excreted in urine, the remainder in feces via bile. Hydrochlorothiazide: Primarily by renal excretion (50-70% unchanged).
Half life
Olmesartan: Approximately 13 hours. Hydrochlorothiazide: Approximately 5.8-14.8 hours.
Absorption
Olmesartan: Rapidly and completely converted to olmesartan during absorption from the gastrointestinal tract. Bioavailability is approximately 26%. Peak plasma concentrations are reached in 1-2 hours. Hydrochlorothiazide: Rapidly absorbed from the GI tract. Bioavailability is 50-80%. Peak plasma concentrations are reached in 1-2.5 hours.
Metabolism
Olmesartan: Olmesartan medoxomil is completely de-esterified to olmesartan. Olmesartan itself undergoes negligible hepatic metabolism. Hydrochlorothiazide: Not metabolized; excreted unchanged.
Side Effects
Contraindications
- •Hypersensitivity to olmesartan, hydrochlorothiazide, or any sulfonamide-derived drugs
- •Pregnancy (second and third trimesters)
- •Severe renal impairment (creatinine clearance <30 mL/min)
- •Anuria
- •Severe hepatic impairment
- •Biliary obstructive disorders
- •Concomitant use with aliskiren in patients with diabetes or renal impairment
Drug Interactions
NSAIDs
Reduced antihypertensive effect of Olmecar-Plus, potential for worsening renal function.
Lithium
Increased serum lithium concentrations and toxicity.
Corticosteroids, ACTH
Enhanced electrolyte depletion, particularly hypokalemia (with hydrochlorothiazide).
Other antihypertensives
Additive blood pressure lowering effect.
Alcohol, barbiturates, narcotics
Potentiation of orthostatic hypotension.
Insulin/Oral antidiabetic agents
May require dose adjustment of antidiabetic drugs (with hydrochlorothiazide).
Potassium-sparing diuretics/Potassium supplements
Increased risk of hyperkalemia (with olmesartan).
Storage
Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension, dizziness, palpitation, and electrolyte disturbances (hypokalemia, hypochloremia, hyponatremia) and dehydration. Treatment is symptomatic and supportive. Induce emesis or perform gastric lavage. Administer activated charcoal. Correct fluid and electrolyte imbalances.
Pregnancy & Lactation
Pregnancy: Category D. Discontinue as soon as pregnancy is detected due to risk of fetal harm and death. Lactation: Not recommended. It is unknown if olmesartan is excreted in human milk. Hydrochlorothiazide is excreted in human milk and may suppress lactation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the date of manufacture
Availability
Available in pharmacies worldwide
Approval Status
Approved by major regulatory bodies (e.g., FDA, DGDA in Bangladesh)
Patent Status
Generic versions available, original patent expired
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in